Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Holmium-166-DOTMP
- Development stage
- Phase 3
- Lead developer
- Poniard Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Holmium-166-DOTMP is an experimental radiopharmaceutical developed for skeletal targeted radiotherapy (STR), primarily in combination with high-dose chemotherapy. It consists of the chelating agent DOTMP, which localizes to bone, and the radioactive isotope holmium-166, a beta-emitting radionuclide. When administered, the compound accumulates in bone tissue and delivers localized ionizing radiation to tumor sites within the bone and bone marrow. This mechanism is intended to destroy cancer cells—particularly myeloma cells—in these locations. The drug was developed by NeoRx Corporation (originator Dow Chemical) as a potential treatment for multiple myeloma and other cancers with skeletal involvement. Clinical development reached phase 3 trials for multiple myeloma but was discontinued before approval[1][2][3][4].
- Other names
- Skeletal targeted radiotherapySTR
Beyond the preview
Go deeper on Holmium-166-DOTMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Holmium-166-DOTMP.